Prevalence of atherosclerotic vascular disease among subjects with the metabolic syndrome with or without diabetes mellitus: The METS-GREECE multicentre study

Current Medical Research and Opinion

Volumn 20, Issue 11, 2004, Pages 1691-1701

  Athyros, Vasilios G ^a,e,f,g   Mikhailidis, Dimitri P ^b,e   Papageorgiou, Athanasios A ^a,e,f   Didangelos, Triandafillos P ^a   Ganotakis, Emmanuel S ^c,e,f   Symeonidis, Athanasios N ^f   Daskalopoulou, Stella S ^b,e   Kakafika, Anna I ^a,e   Elisaf, Moses ^d,e,f  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c UNIVERSITY OF CRETE   (Greece)

^d UNIVERSITY OF IOANNINA   (Greece)

^e Hellenic Atherosclerosis Society   (Greece)

^f Greek Soc of General Practitioners   (Greece)

^g NONE   (Greece)

Author keywords

Diabetes mellitus; Dyslipidaemia; Hypertension; Mediterranean; Metabolic syndrome; Uric acid; Vascular disease

Indexed keywords

CARDIOVASCULAR AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; SULFONYLUREA;

ADULT; AGE; AGED; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMPARATIVE STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DEMOGRAPHY; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; GREECE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PREVALENCE; SEX DIFFERENCE; VASCULAR DISEASE;

EID: 10044279220     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079904X5599     Document Type: Article

References (52)

1. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001;24:683-9
2. Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. J Am Med Assoc 2002;288:2709-16
3. Trevisan M, Liu J, Bahsas FB, Menotti A. Syndrome X and mortality: a population-based study. Am J Epidemiol 1998;148:958-66
4. Ford ES. The metabolic syndrome and mortality from cardiovascular disease and all-causes: findings from the National Health and Nutrition Examination Survey II Mortality Study. Atherosclerosis 2004;73:307-12
5. Alexander CM, Landsman PB, Teutsch SM, Haffner SM; Third National Health and Nutrition Examination Survey (NHANES III); National Cholesterol Education Program (NCEP). NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50years and older. Diabetes 2003;52:1210-4
6. Ninomiya JK, L'Italien G, Criqui MH, Whyte JL, Gamst A, Chen RS. Association of the metabolic syndrome with history of myocardial infarction and stroke in the third national health and nutrition examination survey. Circulation 2004;109:42-6
7. Hunt KJ, Resendez RG, Williams K, Haffner SM, Stern MP. NCEP versus WHO metabolic syndrome in relation to all cause and cardiovascular mortality in the San Antonio Heart Study (SAHS) [abstract]. Diabetes 2003;52:A221-28. Resnick HE, Jones K, Ruotolo G, et al. Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease in nondiabetic American Indians. The Strong Heart Study. Diabetes Care 2003;26:861-7
8. Hunt KJ, Resendez RG, Williams K, Haffner SM, Stern MP. NCEP versus WHO metabolic syndrome in relation to all cause and cardiovascular mortality in the San Antonio Heart Study (SAHS) [abstract]. Diabetes 2003;52:A221-28. Resnick HE, Jones K, Ruotolo G, et al. Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease in nondiabetic American Indians. The Strong Heart Study. Diabetes Care 2003;26:861-7
9. Deedwania PC. Metabolic syndrome and vascular disease: is nature or nurture leading the new epidemic of cardiovascular disease? Circulation 2004;109:2-4
10. Athyros VG, Bouloukos VI, Pehlivanidis AN, et al. for the MetS-GREECE Collaborative Group. The prevalence of the METabolic Syndrome in GREECE-The MetS - GREECE Multicenter Study. Diab Obesity Metab 2004 [in press]
11. Athyros VG, Elisaf M, Mikhailidis DP. Undertreatment of dyslipidaemia in Greece. Atherosclerosis 2004 [in press]
12. Adult Treatment Panel III. The third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. J Am Med Assoc 2001;285:2486-97
13. Expert Committee on the Diagnosis and the Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and the classification of diabetes mellitus. Diabetes Care 1997;20:1183-97
14. Greek population data set. Available from http://www.kethi.gr/greek/ statistika/Apasxolisi/APOGRAFI_01.htm [accessed 13 Aug 2004]
15. PROCAM risk calculator. Available from: http://chdrisk.uni-muenster.de/ risk.php [accessed 13 August 2004]
16. Kip KE, Marroquin OC, Kelley DE, et al. Clinical importance of obesity vs the metabolic syndrome in cardiovascular risk in women: a report from the Women's Ischemia Syndrome Evaluation (WISE) study. Circulation 2004;109:706-13
17. Daly P, Solomon C, Manson J. Risk modification in the obese patient. In: Manson J, Ridker P, Gaziano J, editors. Prevention of myocardial infarction. New York: Oxford University Press; 1996. pp. 203-40
18. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol: a meta-analysis population-based prospective studies. J Cardiovasc Risk 1996;3:213-9
19. Olijhoek JK, van der Graaf Y, Banga JD, Algra A, Rabelink TJ, Visseren FLJ for the SMART Study Group. The Metabolic Syndrome is associated with advanced vascular damage in patients with coronary heart disease, stroke, peripheral arterial disease or abdominal aortic aneurysm. Eur Heart J 2004;25:342-8
20. Sakkinen PA, Wahl P, Cushman M, Lewis MR, Tracy RP. Clustering of procoagulation, inflammation, and fibrinolysis variables with metabolic factors in insulin resistance syndrome. Am J Epidemiol 2000;152:897-907
21. Bonora E, Kiechl S, Willeit J, et al. Metabolic syndrome: epidemiology and more extensive phenotypic description. Cross-sectional data from the Bruneck Study. Int J Obes Relat Metab Disord 2003;27:1283-9
22. Onat A, Ceyhan K, Basar O, Erer B, Toprak S, Sansoy V. Metabolic syndrome: major impact on coronary risk in a population with low cholesterol levels - a prospective and cross-sectional evaluation. Atherosclerosis 2002;165:285-92
23. Daskalopoulou SS, Mikhailidis DP, Elisaf M. Prevention and treatment of the metabolic syndrome. Angiology 2004 [in press]
24. Kwiterovich Jr PO. Clinical relevance of the biochemical, metabolic, and genetic factors that influence low-density lipoprotein heterogeneity. Am J Cardiol 2002;90:30i-47
25. Girman CJ, Rhodes T, Mercuri M, et al. for the 4S Group and the AFCAPS/TexCAPS Research Group. The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol 2004;93:136-41
26. Ballantyne CM, Olsson AG, Cook TJ, Mercuri MF, Pedersen TR, Kjekshus J. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation 2001;104:3046-51
27. Sattar N, Gaw A, Scherbakova O, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003;108:414-9
28. Wong ND, Pio JR, Franklin SS, L'Italien GJ, Kamath TV, Williams GR. Preventing coronary events by optimal control of blood pressure and lipids in patients with the metabolic syndrome. Am J Cardiol 2003;91:1421-6
29. Janssen I, Katzmarzyk PT, Ross R. Waist circumference and not body mass index explains obesity-related health risk. Am J Clin Nutr 2004;79:379-84
30. Lofgren I, Herron K, Zern T, et al. Waist circumference is a better predictor than body mass index of coronary heart disease risk in overweight premenopausal women. J Nutr 2004;134:1071-6
31. Ross R, Katzmarzyk PT Cardiorespiratory fitness is associated with diminished total and abdominal obesity independent of body mass index. Int J Obes 2003;27:204-10
32. Kanaya AM, Vittinghoff E, Shlipak MG, et al. Association of total and central obesity with mortality in postmenopausal women with coronary heart disease. Am J Epidemiol 2003;158:1161-70
33. Ramachandran A, Snehalatha C, Satyavani K, et al. Metabolic syndrome in urban Asian Indian adults - a population study using modified ATP III criteria. Diabetes Res Clin Pract 2003;60:199-204
34. Lee WY, Park JS, Noh SY, Rhee EJ, Kim SW, Zimmet PZ. Prevalence of the metabolic syndrome among 40 698 Korean metropolitan subjects. Diabetes Res Clin Pract 2004;65:143-9
35. Janssen I, Katzmarzyk PT, Ross R. Body mass index, waist circumference, and health risk evidence in support of current National Institutes of Health guidelines. Arch Intern Med 2002;162:2074-9
36. UKPDS risk calculator. Available from: http://www.dtu.ox.ac.uk/index. html?maindoc=/ukpds/ [Accessed 13 August 2004]
37. Ballantyne CM, Hoogeveen RC. Role of lipid and lipoprotein profiles in risk assessment and therapy. Am Heart J 2003;146:227-33
38. Ballantyne CM, Andrews TC, Hsia JA, Kramer JH, Shear C; ACCESS Study Group. Atorvastatin Comparative Cholesterol Efficacy and Safety Study. Correlation of non-high-density lipoprotein cholesterol with apolipoprotein B: effect of 5 hydroxymethylglutaryl coenzyme A reductase inhibitors on non-high-density lipoprotein cholesterol levels. Am J Cardiol 2001;88:265-9
39. Cui Y, Blumenthal RS, Flaws JA, et al. Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch Intern Med 2001;161:1413-9
40. Athyros VG, Papageorgiou AA, Mercouris BR, et al. Treatment with atorvastatin to the National Cholesterol Educational Program goals versus usual care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. Curr Med Res Opin 2002;18:220-8
41. Athyros VG, Papageorgiou A, Symeonidis A, Elisaf M. Non-high density lipoprotein cholesterol and coronary events during long-term statin treatment. Atherosclerosis 2003;168:397-8
42. Klein BE, Klein R, Lee KE. Components of the metabolic syndrome and risk of cardiovascular disease and diabetes in Beaver Dam. Diabetes Care 2002;25:1790-4
43. Nakanishi N, Takatorige T, Fukuda H, et al. Components of the metabolic syndrome as predictors of cardiovascular disease and type 2 diabetes in middle-aged Japanese men. Diabetes Res Clin Pract 2004;64:59-70
44. Malik S, Wong ND, Franklin SS, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States Adults. Circulation 2004 Aug 23 [Epub ahead of print]
45. Athyros VG, Papageorgiou AA, Symeonidis AN, et al. for the GREACE study collaborative Group. Early benefit from structured care with atorvastatin in patients with coronary heart disease and diabetes mellitus. Angiology 2003;54:679-90
46. Robins SJ, Rubins HB, Faas FH, et al.; Veterans Affairs HDL Intervention Trial (VA-HIT). Insulin resistance and cardio-vascular events with low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT). Diabetes Care 2003;26:1513-7
47. Rubins HB, Robins SJ, Collins D, et al. Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). Arch Intern Med 2002;162:2597-604
48. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial. Lancet 2003;361:2005-16
49. Sever PS, Dahlof B, Poulter NR, et al.; ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multi-centre randomised controlled trial. Lancet 2003;361:1149-58
50. UK HDL-C Consensus Group. Role of fibrates in reducing coronary risk: a UK consensus. Curr Med Res Opin 2004;20:241-7
51. Milionis HJ, Daskalopoulou SS, Elisaf M, Mikhailidis DP. The predictive value of lipid markers. Curr Pharm Des 2004 [in press]
52. Fowkes FG, Housley E, Cawood EH, Macintyre CC, Ruckley CV, Prescott RJ. Edinburgh Artery Study: prevalence of asymptomatic and symptomatic PAD in the general population. Int J Epidemiol 1991;20:384-92